source
- ADARx aims for $318 million IPO as TRexBio and Retension also fileADARx Pharmaceuticals, a siRNA biotech currently in Phase 3 trials, announced plans to raise roughly $318 million through an initial public offering. The company is joining other biotech firms suc…
- Novo outlines diversification strategy with new pipeline assets and bolt-on dealsNovo Pharmaceuticals' chief executive Maziar Mike Doustdar used the company's recent capital-markets day in London to lay out a diversification plan. He said the rebranded firm will focus on expand…